James Kramer - Concepedia

Author

James Kramer

Charles River Laboratories (United States)

Also Known As

J. Kramer, J. Krämer, J. W. Kramer, James Kramer, James W. Kramer, Kramer, James W.

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

Charles River Laboratories (United States)Center for Drug Evaluation and Research WesTest Engineering (United States)University of Oxford Nanion (Germany)

About

James Kramer is an author at Charles River Laboratories (United States) specializing in drug discovery, medicine, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	1	1	166
2	Pharmacology	1	1	166
3	Drug Discovery	1	1	166
4	Cardiovascular Pharmacology	1	1	166
5	Pharmacotherapy	1	1	166

James Kramer

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
MICE Models: Superior to the HERG Model in Predicting Torsade de Pointes James Kramer, Carlos A. Obejero‐Paz, Glenn J. Myatt, Scientific Reports	2013	345
Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes Kimberly R. Doherty, Robert Wappel, Dominique R. Talbert, Toxicology and Applied Pharmacology CardiomyopathyMedicineCardiovascular PharmacologyVitro Toxicity TestingHuman Cardiomyocytes	2013	166
Assessment of an <i>In Silico</i> Mechanistic Model for Proarrhythmia Risk Prediction Under the Ci<scp>PA</scp> Initiative Zhihua Li, Bradley J. Ridder, Xiaomei Han, Clinical Pharmacology & Therapeutics	2018	166
Modulation of potassium channel gating by coexpression of Kv2.1 with regulatory Kv5.1 or Kv6.1 α-subunits James Kramer, Marc Post, Arthur Brown, American Journal of Physiology-Cell Physiology	1998	116
Alfuzosin Delays Cardiac Repolarization by a Novel Mechanism Antonio E. Lacerda, Yuri A. Kuryshev, Yuan Chen, Journal of Pharmacology and Experimental Therapeutics	2007	93
Cross-site and cross-platform variability of automated patch clamp assessments of drug effects on human cardiac currents in recombinant cells James Kramer, Herbert M. Himmel, Anders Lindqvist, Scientific Reports	2020	59
A systematic strategy for estimating hERG block potency and its implications in a new cardiac safety paradigm Bradley J. Ridder, Derek J. Leishman, Matthew Bridgland‐Taylor, Toxicology and Applied Pharmacology	2020	45
Quantitative Profiling of the Effects of Vanoxerine on Human Cardiac Ion Channels and its Application to Cardiac Risk Carlos A. Obejero‐Paz, Andrew Bruening‐Wright, James Kramer, Scientific Reports	2015	39
Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off‐label in the first wave of COVID‐19 Annie Delaunois, Matthew M. Abernathy, Warren D. Anderson, Clinical and Translational Science	2021	34
A general procedure to select calibration drugs for lab-specific validation and calibration of proarrhythmia risk prediction models: An illustrative example using the CiPA model Xiaomei Han, Mohammadreza Samieegohar, Bradley J. Ridder, Journal of Pharmacological and Toxicological Methods	2020	17

Page 1